New RNA-based active agents reliably protect plants against the Cucumber mosaic virus (CMV), the most common virus in ...

Both microRNAs and the related class of small interfering RNAs (siRNAs) are small snippets of RNA—just 21 or 22 nucleotides long—that bind to specific messenger RNAs (mRNAs) and repress them.

Researchers at Martin Luther University have developed groundbreaking RNA-based agents that offer high levels of protection ...

Privately-held Chinese firm Visirna Therapeutics has announced that a Phase III trial of VSA001 (plozasiran) has met both its ...

Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) for RN0361-an APOC3 ...

A new study published in the Journal of American Medical Association showed that the innovative small interfering RNA (siRNA) medication olpasiran (Amgen) can effectively reduce lipoprotein(a) ...

The following is a summary of "Impact of HBsAg reduction via siRNA treatment on natural and vaccine (BRII-179)-induced ...

Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort Multi-dosing ongoing in 200 mg cohort of RestorAATion-2 ...

BACKGROUND: Lymphedema is an incurable disease associated with lymphatic dysfunction that causes tissue swelling and fibrosis ...

H.C. Wainwright reiterates a Buy rating and $80 price target on shares of Arrowhead (ARWR) Pharmaceuticals after the company announced top-line ...

New RNA-based active agents reliably protect plants against the Cucumber mosaic virus (CMV), the most common virus in agriculture and horticulture. They were developed by researchers at the Martin ...